Technical Pitfalls of Signal Truncation in Perfusion MRI of Glioblastoma by Kelvin K. Wong et al.
August 2016 | Volume 7 | Article 1211
Original research
published: 02 August 2016
doi: 10.3389/fneur.2016.00121
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Kerrie Leanne McDonald, 
University of New South Wales, 
Australia
Reviewed by: 
Kamalakannan Palanichamy, 
Ohio State University, USA  
David D. Eisenstat, 
University of Alberta, Canada
*Correspondence:
Kelvin K. Wong  
kwong@houstonmethodist.org
Specialty section: 
This article was submitted to 
Neuro-Oncology, 
a section of the journal 
Frontiers in Neurology
Received: 02 March 2016
Accepted: 20 July 2016
Published: 02 August 2016
Citation: 
Wong KK, Fung SH, New PZ and 
Wong STC (2016) Technical Pitfalls of 
Signal Truncation in Perfusion MRI of 
Glioblastoma. 
Front. Neurol. 7:121. 
doi: 10.3389/fneur.2016.00121
Technical Pitfalls of signal Truncation 
in Perfusion Mri of glioblastoma
Kelvin K. Wong1,2,3*, Steve H. Fung1,2, Pamela Z. New3 and Stephen T. C. Wong1,2
1 Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Houston, TX, USA, 
2 Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY, USA, 3 Department of Neurological 
Surgery, Weill Cornell Medicine, Cornell University, New York, NY, USA
Dynamic susceptibility contrast (DSC) perfusion-weighted imaging (PWI) is widely used 
in clinical settings for the radiological diagnosis of brain tumor. The signal change in 
brain tissue in gradient echo-based DSC PWI is much higher than in spin echo-based 
DSC PWI. Due to its exquisite sensitivity, gradient echo-based sequence is the preferred 
method for imaging of all tumors except those near the base of the skull. However, high 
sensitivity also comes with a dynamic range problem. It is not unusual for blood volume to 
increase in gene-mediated cytotoxic immunotherapy-treated glioblastoma patients. The 
increase of fractional blood volume sometimes saturates the MRI signal during first-pass 
contrast bolus arrival and presents signal truncation artifacts of various degrees in the 
tumor when a significant amount of blood exists in the image pixels. It presents a hidden 
challenge in PWI, as this signal floor can be either close to noise level or just above and 
can go no lower. This signal truncation in the signal intensity time course is a significant 
issue that deserves attention in DSC PWI. In this paper, we demonstrate that relative 
cerebral blood volume and relative cerebral blood flow (rCBF) are underestimated due 
to signal truncation in DSC perfusion, in glioblastoma patients. We propose the use of 
second-pass tissue residue function in rCBF calculation using least-absolute-deviation 
deconvolution to avoid the underestimation problem.
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inTrODUcTiOn
Dynamic susceptibility contrast (DSC) perfusion-weighted imaging (PWI) is widely used in the 
radiological diagnosis of brain tumors in addition to contrast-enhanced MRI and morphological 
MRI. In therapeutic monitoring of brain tumors, the long standing problem is how to differentiate 
tumor recurrence and pseudoprogression after chemoradiation as all of these scenarios will show 
contrast enhancement in MRI. The literature regarding the use of perfusion to differentiate these 
confusing scenarios has been shown to be very useful (1–5). Machine learning-based method in the 
differentiation showed that perfusion measurements, such as relative cerebral blood volume (rCBV) 
and relative cerebral blood flow, are indeed more useful than contrast enhancement (2). Dynamic 
contrast enhancement (DCE) permeability mapping also showed some promise in the area (6), 
though it was not directly compared to DSC perfusion. The variable success in application of DSC 
perfusion in distinguishing progression from pseudoprogression may rest on the details of how the 
perfusion studies are post-processed, leading to the difficulties in comparing results across studies 
(7). Standardization of post-processing algorithms along with injection and imaging protocols are 
important issues to application of DSC perfusion in brain tumors diagnosis.
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Among the three cerebral hemodynamics parameters derived 
from DSC perfusion: rCBV, relative cerebral blood flow (rCBF), 
and mean transit time (MTT), rCBV is the most stable, as it is 
computed by the area under the curve of the contrast concen-
tration time course normalized to the area under the arterial 
input function (AIF). There are various methods, including 
deconvolution-based methods (8–10) and the tissue residue 
function model-based method (11), to derive rCBF and MTT. 
Due to the impulse response nature of the tissue residue function, 
which has a sharp rising edge at contrast arrival, and the limited 
temporal resolution, all of these methods will underestimate 
the peak of the tissue residue function, which leads to severe 
underestimation of rCBF at high flow rate compared to lower flow 
rate (8–10). One way to resolve this issue is to have an accurate 
estimation of bolus arrival time (12), removing one parameter 
from the deconvolution of the tissue residue function, as a small 
error in the estimation of bolus arrival time can change the rCBF 
estimates significantly (13).
In clinical settings, the signal change in brain tissue in gradient 
echo DSC PWI is much higher than spin echo DSC PWI. Due 
to this exquisite sensitivity of gradient echo sequence, a lower 
contrast dose is required. Typically, spin echo DSC PWI is about 
half the sensitivity of gradient echo DSC PWI, with the former 
requiring injecting 2× the volume of contrast agent at the same 
concentration. Therefore, DSC PWI is a preferred method except 
at the base of the skull or other locations where the air–tissue 
interface causes significant signal dropout.
However, high sensitivity also comes with the dynamic range 
problem. Typical white matter and gray matter have about 2.5–5% 
fractional blood volume, and it is typical to tune the imaging 
parameters to obtain 30–60% signal drop in different brain tis-
sues. Therefore, it is very common for the tumor signal intensity 
time course in gradient echo DSC PWI to drop to a noise level 
in pixels with a significant amount of blood volume, especially 
in pixels with rich venous blood or in the case of intratumoral 
hemorrhage. It presents a hidden challenge in PWI as the signal 
intensity time course can drop to a signal floor or noise floor level. 
In the first scenario, the average signal from the pixel is signifi-
cantly above noise level because part of the pixel is occupied by 
a blood vessel. This signal truncation in the signal intensity time 
course is a significant issue that deserves attention in DSC PWI. 
In this paper, we demonstrate the effects of signal truncation in 
DSC perfusion studies of glioblastoma patients undergoing gene-
mediated cytotoxic immunotherapy studies. The impact on CBF 
estimation is determined by the recirculating second pass of the 
tissue residue function when contrast leakage correction is used.
MaTerials anD MeThODs
Theory
To measure cerebral hemodynamic parameters, DSC perfusion 
image pixel intensity needs to be converted to the concentration 
of contrast in the tissue. The relationship between signal intensity 
S(t) and concentration C(t) is defined by:
 S t S e( ) = ( )×0 - kC t TE  (1)
where S0 is the image intensity before contrast injection, k is a 
constant, and TE is the echo time. The tissue contrast concentra-
tion C(t) can be expressed as a convolution of the AIF with a 
tissue residue function R(t) multiplied by CBF:
 
C t F AIF R t dt
t
( ) ( ) ( )= −∫ τ τ τ
0  
(2)
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where h(t) is the transport function or the probability distribu-
tion of transit time in the tissue and Ft is the cerebral blood flow 
(CBF). The tissue contrast concentration C(t) can be expressed 
as the convolution of the AIF, Ca(t), with a residue function R(t) 
multiplied by CBF.
C t
C t
C t
t
C t
C t C t
( )
( )
( )
( )
( ) ( )
0
1
1
0
1 0
0 0
0


…
N
a
a a
−














= ∆
   


C t C t C t
R t
R t
R ta N a N a N( ) ( ) ( )
( )
( )
(− −














×
1 2 0
0
1
−













1)
Ft
 
(5)
which can be simplified to c = A⋅r and CBF can be estimated as 
the maximum value of r.
The CBF rate can be estimated by a perfusion deconvolution 
algorithm using least-absolute-deviation (LAD) regularization 
(10), which allows more accurate estimation at high blood vol-
ume and high flow rate. LAD regularization can be achieved by 
minimizing the following functional:
 
r Ar c Lr
rλ
λ= − +{ }min 1 1  (6)
where L1 norm is defined as || || | |x xi
i
n
1
1
=
=
∑ ; the regularization 
function L is chosen as a first order difference operator and λ 
is the regularization parameter. The minimization problem is 
formulated as a linear programing problem and solved iteratively 
by the interior point method (14).
Note that the ideal tissue residue function R(t) in the absence 
of recirculation is by definition a monotonic decay function, such 
as exponential, boxcar, or triangular functions (10). In the pres-
ence of second-pass recirculation, the measured tissue residue 
function Rm(t) is a summation of the tissue residue function of 
the first pass and the second pass with a time-shift corresponding 
to the vascular delay (Vd) and a Gaussian-like vascular dispersion 
function [D(t)] caused by the recirculation system.
 R t R t D t R t Vm d( ) = ( ) + ( )⊗ −( )  (7)
Assuming the first-pass tissue residue function does not extend 
beyond Vd, which is a reasonable assumption in brain tissue, as Vd 
is at least 20 s in typical adult with normal cardiac output, rCBF 
can be determined as the peak of the second-pass tissue residue 
FigUre 1 | (a) Relative cerebral blood volume map generated from the leakage corrected data, (B) relative cerebral blood flow map determined by the peak of the 
first-pass tissue residue function, and (c) relative cerebral blood flow map determined by the peak of the second-pass tissue residue function. Note the tight 
coupling between blood volume and blood flow.
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function, as the same dispersion function applies linearly on all 
pixels in tissue.
leakage correction in Brain Tumor
Contrast leakage is expected to occur in most brain tumors and it 
is also one of the fundamental criteria to detect the spatial extent 
of brain tumors, clinically. Some brain tumors are non-enhancing 
though glioblastoma are mostly enhancing tumors with some 
non-enhancing components. In the presence of contrast leakage 
to parenchyma in strongly T2*-weighted PWI, the measured 
contrast concentration in tissue, Cm(t), calculated using Eq. 1 can 
be effectively modeled as (15):
 
C t K C t K C t
t
m tissue tissue( ) = ( ) + ( )∫1 2
0  
(8)
where Ctissue(t) is the mean contrast concentration curve of nor-
mal brain tissue including both gray and white matter, K2 is a 
heuristic factor primarily determined by the rate of leakage, such 
as permeability surface area product, etc. The leakage corrected 
tissue contrast concentration C(t) is thus equal to K1Ctissue(t).
clinical cases
To demonstrate the signal truncation effects in rCBF meas-
urements, longitudinal data from glioblastoma patients in 
gene-mediated cytotoxic immunotherapy studies (16) (www.
ClinicalTrials.gov; ID: NCT00751270 and NCT00589875) were 
retrieved from the picture archiving system, retrospectively. 
The DSC perfusion study was conducted in a General Electric 
1.5 T/3.0 T Signa Excite system using a 8-channel head coil. The 
imaging parameters of the 1.5  T protocol are: TR/TE: 1400–
1700 ms/60 ms, 2D single-shot gradient-echo EPI sequence with 
7 mm slice thickness with in-plane resolution of 1.875 mm and the 
3.0 T protocol parameters are TR/TE:1600–2000 ms/40 ms, 2D 
single shot gradient-echo EPI sequence with 5 mm slice thickness 
with same in-plane resolution. Some cases were conducted with a 
power injector where 15 mL contrast agent is injected at 5 mL/s, 
intravenously. The study was approved by the institutional review 
board of the Houston Methodist Hospital.
resUlTs
Figure  1 shows the rCBV and rCBF maps from the first-pass 
and second-pass tissue residue function of a representative 3 T 
case done with a power injector. Note the close resemblance of 
the rCBV and rCBF map generated with the second-pass tissue 
residue function, indicating a tight coupling. Figure 2 shows the 
truncation artifacts on the single-pixel signal time course within 
the time window of [16  s, 34  s] when the contrast bolus pass 
through different pixel locations. The mean noise level was about 
100 au. Various forms of signal truncation are shown at Locations 
1, 3, and 4, while Location 2 is not truncated. The truncation issue 
is very common in areas with high blood volume in tumor tissue, 
especially near blood vessels. Figure 3 shows the effect of signal 
truncation on the tissue residue function. The first-pass tissue 
residue function is essentially truncated near the top, which will 
significantly underestimate rCBF. The first-pass and second-pass 
portion of the tissue residue function are well separated, and the 
second-pass portion of the tissue residue function has a mono-
tonic decay shape after the peak.
Figure 4 shows the rCBV and rCBF maps from the first-pass 
and second-pass tissue residue function of a representative 1.5 T 
case done without using a power injector. The post-contrast 
T1-enhanced region overlapped spatially with high rCBV and 
rCBF regions either using the peak of the first-pass or the second-
pass tissue residue function. This is the worst-case scenario where 
manual injection was not fast enough to allow a clear separation 
between first-pass and second-pass bolus passage. It also vio-
lates the assumptions of a separable second-pass. Nevertheless, 
Figure 5 shows the effect of signal truncation and the eventual 
distortion on the contrast concentration time courses. The leak-
age correction still performs fine as the contrast concentration 
returns to very low level at steady-state in the presence of small 
signal truncation error.
FigUre 3 | Tissue residue functions at locations 2 and 4. Both the 
first-pass [20s, 40s] and second-pass [40s, 60s] of the function are well 
separated.
FigUre 2 | signal intensity time courses of different high blood volume locations and in normal brain tissue. All locations except Location 2 have signal 
truncation artifacts due to high blood volume. Their respective locations are indicated by arrows in Figure 1.
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DiscUssiOn
One factor that limits our ability to quantify CBF, CBV, and 
MTT from DSC perfusion studies is the necessity of measuring 
the signal in the artery (i.e., AIF) that feeds the tissue of interest, 
whose shape depends on injection speed, cardiac output, etc. It 
has been shown that errors in selecting the AIF can be among the 
largest sources of error in the derived measurements of CBV, CBF, 
and MTT. Truncation of the AIF shape has a profound effect on 
the maps generated.
Truncation of the tissue signal time course also has a profound 
effect on the maps generated. This problem is less addressed in 
the literature as the effect is quite different on a pixel-to-pixel 
basis depending on the severity of truncation. The various shapes 
and form of truncation can be hard to recognize as saturation of 
contrast agent in part of a pixel is not equivalent to signal hitting 
the floor as partial volume effect determines the ultimate signal 
behavior. Image pixels with a large blood-containing fraction 
are more likely to have signal truncation artifacts. Truncation 
in the AIF can be mitigated to some extent by fitting the first-
pass portion of the AIF using the gamma-variate function (17), 
which is also used in this study. Truncation in the tissue level is, 
however, difficult to compensate as the tissue residue function 
is unknown, and it can greatly affect the shape and form of the 
contrast concentration curves.
The proposed extension to the LAD deconvolution method 
works well in brain tumor cases that are based on the assumption 
that there is little overlap between the first-pass and second-pass 
portions of the tissue residue function. It applies generally where 
the contrast bolus is injected quickly with the help of a power 
injector where the first-pass and second-pass contrast passage are 
well separated. In tissue ischemia, where the MTT is very long, i.e., 
the tissue residue function has a long tail, there will be significant 
overlaps between the first-pass and second-pass portion. This 
limits application in tissue with known long transit time, such as 
choroid plexus, or in ischemic tissue. Note that this assumption 
is implicitly used in leakage correction, which models that the 
contrast concentration time course in tumor tissue is propor-
tional to the contrast concentration time course of normal tissue. 
Therefore, leakage correction should be used and interpreted with 
caution near tissue with long transit time in brain tumor cases.
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In addition, we would like to point out that, in LAD deconvo-
lution of tissue residue function, temporal signal-to-noise ratio 
and the temporal contrast change during bolus passage are two 
important factors for the method to work properly rather than 
static image signal-to-noise ratios. To quantify the tissue residue 
function in more detail, one would need higher temporal resolu-
tion while simultaneously addressing the accompanying T1 leak-
age effects in tumor cases (18). Table 1 shows a summary of the 
technical pitfalls and potential solutions discussed in this paper.
One notable effect of using the second-pass tissue residue 
function in determining rCBF is that the major veins are sup-
pressed. This is obvious in the suppression of sagittal sinus in 
Figure  1C compared to Figure  1B. This is understandable as 
major veins effectively collect the blood after the passage of the 
bolus through the whole brain and have significantly higher 
vascular dispersion. Sagittal sinus is the most suppressed. It is 
FigUre 4 | (a) T1-weighted post-contrast MRI showing the location of suspected tumor. The suspected enhanced region has a hot spot area in the (B) relative 
blood volume map as well as in the (c) relative cerebral blood flow map determined by the peak of the first-pass tissue residue function as well from the (D) second-
pass tissue residue function.
FigUre 5 | contrast concentration time courses of locations 1–3 indicated in Figure 4B before and after contrast leakage correction. Signal 
truncation artifact at these locations results in a disruption of the contrast concentration time course. The effect of leakage correction is obvious with minimal 
contrast concentration after the first and second passes of the bolus.
TaBle 1 | summary of technical pitfalls and potential solutions.
Pitfalls solutions
Arterial input function 
truncation (AIF)
Fitting AIF with a Gamma-variate function
Brain tissue signal time 
course truncation
1. Leakage correction
2. Calculate rCBF and rCBV using second-
pass tissue residue function
also noteworthy that, in the calculation of rCBV, signal trunca-
tion artifacts in major veins will also cause a truncation in the 
contrast concentration time curve, leading to underestimation 
of rCBV. This may have significant implications in tumor rCBV 
interpretation. The underestimation of rCBV due to signal 
truncation is less severe than the case in rCBF. It has been shown 
that rCBV and rCBF are two of the most important parameters 
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to differentiate pseudoprogression and tumor recurrence in 
glioblastoma patients, after  chemoradiation (2, 4–6). Radiation 
necrosis is associated with low rCBV and rCBF. Gross under-
estimation of rCBV and rCBF due to signal truncations would 
bias the diagnosis toward pseudoprogression, systematically. 
However, perfusion change during immunotherapy in glioblas-
toma could be therapy–specific, and more studies are needed 
to understand the role of perfusion imaging to monitor disease 
progression.
To summarize, we propose the use of second-pass tissue residue 
function in rCBF calculation using LAD deconvolution method. 
This strategy is used to circumvent the practical limitations in 
DSC PWI, where signal truncation artifacts occur often in high 
blood volume regions. The issue has not received much attention 
in the literature, and the problem is more severe in high-grade 
brain tumor where the rCBV is very high. Implications of signal 
truncation in high blood volume regions leading to underestima-
tion in rCBV and rCBF are discussed. In the absence of severe 
tissue ischemia, rCBF maps derived from second-pass tissue 
residue function may be a useful alternative. By paying attention 
to the technical pitfalls described in this paper, rCBV and rCBF 
underestimations can be avoided. Unbiased estimations of rCBF 
and rCBV are crucial to differentiate pseudoprogression from 
tumor recurrence.
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